Ethiopia MABR wastewater deal marks international expansion for Emefcy
Israeli wastewater treatment company Emefcy has signed a contract for its Membrane Aerated Biofilm Reactor to be used at a hospital in Ethiopia...
ADDIS ABABA, Ethiopia - Israeli wastewater treatment company Emefcy has signed a contract for its Membrane Aerated Biofilm Reactor (MABR) to be used at the Ayder Hospital at Mekele University in Tigray, Ethiopia.
Once installed, the 320 m3/day MABR system will treat wastewater from Mekele University Hospital, which also plans to reuse the treated water for irrigation and toilet flushing on the hospital’s grounds.
The contract will generate revenue of approximately AUS$430K (US$321,400) and is scheduled to be commissioned by the end of this year.
The company has set a 2016 financial goal of AU$1m (US$747,450) and said the Ethiopian contract has helped it meet the target.
Local company Today-Tomorrow Ventures in Ethiopia will jointly manage the project.
The MABR technology is a spirally-wound sleeve with an internal air-side spacer, through which low pressure air is blown. The spiral is submerged in a tank to which wastewater is fed continuously and effluent is discharged by overflow.
According to the company, this saves energy by “eliminating the need to blow compressed air into the depth of the water for aeration, through the implementation of Emefcy's patented passive aeration process”.
The installation represents Emefcy’s first deal outside of Israel and is double the size of the company’s wastewater treatment installation at Ha-Yogev, Israel.
The next MABR project in the production phase is in the US Virgin Islands, which is expected to be operated by Q4 2016.
Eytan Levy, CEO of Emefcy, said: “Ethiopia represents a large opportunity for Emefcy’s decentralized MABR-based wastewater treatment solutions, due to its lack of sewage handling infrastructure.”